Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Bioorg Chem ; 121: 105686, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-35217376

RESUMO

Nine different isoquinoline alkaloids, berberine, govaniadine, stylopine, adlumine, adlumidine, bicuculline, sanguinarine, protopine and californidine have been evaluated for their effects on a cellular model of hepatocyte for their effect on low density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) expression compared to simvastatin. Berberine, californidine and govaniadine induced LDLR with an effect similar to 2.5 µM simvastatin. Californidine and berberine at tested doses reduced the expression of PCSK9, with an opposite behaviour to simvastatin on this target. Govaniadine, on the other hand, showed a statin-like effect, although less potently, by increasing both LDLR and PCSK9 levels. Berberine californidine and govaniadine were then tested on the same cellular model to assess possible effect of reduction of total cholesterol, compared to simvastatin. All compounds were able to reduce total cholesterol level in the hepatocytes.


Assuntos
Berberina , Pró-Proteína Convertase 9 , Berberina/metabolismo , Berberina/farmacologia , Colesterol/farmacologia , Hepatócitos , Isoquinolinas , Pró-Proteína Convertase 9/metabolismo , Receptores de LDL/metabolismo , Sinvastatina/metabolismo , Sinvastatina/farmacologia , Subtilisina/metabolismo , Subtilisina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA